The FDA's antibiotic resistance
In: Regulation: the Cato review of business and government, Band 27, Heft 4, S. 34-37
Abstract
Argues that current demand-side policy of the Food and Drug Administration and the Centers for Disease Control is the wrong route to address the issue of antibiotic resistance as it reduces the value to a pharmaceutical company of investing in the creation of new antibiotics. In this light, three externalities associated with antibiotic usage are discussed: public health, antibiotic resistance, and supply-side externalities. A cost-benefit analysis of FDA policies related to increased antibiotic scrutiny ensues, finding that requiring additional testing for antibiotics makes little sense with respect to patient welfare. Two harmful effects on antibiotic resistance of this FDA policy are denying the market use of an additional antibiotic, Ketek, and the loss of pharmaceutical company incentive to develop new antibiotics.
Themen
Pharmaceutical industry, Antibiotics, Economic aspects, United States, Food and drug administration
Sprachen
Englisch
ISSN: 0147-0590
Problem melden